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Bilirubin, the end-product of heme catabolism, circulates in non-pathological plasmamostly
as a protein-bound species.When bilirubin concentration builds up, the free fraction of the
molecule increases. Unbound bilirubin then diffuses across blood–brain interfaces (BBIs)
into the brain, where it accumulates and exerts neurotoxic effects. In this classical view of
bilirubin neurotoxicity, BBIs act merely as structural barriers impeding the penetration of
the pigment-bound carrier protein, and neural cells are considered as passive targets of its
toxicity. Yet, the role of BBIs in the occurrence of bilirubin encephalopathy appears more
complex than being simple barriers to the diffusion of bilirubin, and neural cells such as
astrocytes and neurons can play an active role in controlling the balance between the neu-
roprotective and neurotoxic effects of bilirubin.This article reviews the emerging in vivo and
in vitro data showing that transport and metabolic detoxiﬁcation mechanisms at the blood–
brain and blood–cerebrospinal ﬂuid barriers may modulate bilirubin ﬂux across both cellular
interfaces, and that these protective functions can be affected in chronic unconjugated
hyperbilirubinemia. Then the in vivo and in vitro arguments in favor of the physiological
antioxidant function of intracerebral bilirubin are presented, as well as the potential role
of transporters such as ABCC1 and metabolizing enzymes such as cytochromes P-450 in
setting the cerebral cell- and structure-speciﬁc toxicity of bilirubin following hyperbilirubine-
mia. The relevance of these data to the pathophysiology of bilirubin-induced neurological
diseases is discussed.
Keywords: ABC transporters, astrocyte, biliverdin, blood–brain barrier, choroid plexus, glutathione-S-transferase,
OATP, UDP-glucuronosyltransferase
INTRODUCTION
Unconjugated bilirubin (UCB) is the end-product of heme catab-
olism, and is eliminated from the body following hepatic con-
jugation to glucuronic acid. When UCB clearance is inefﬁcient,
plasma UCB concentration increases markedly, and brain dam-
age may ensue. This most frequently occurs in severe jaundice
of the neonate, or in cases of severe congenital impairment of
bilirubin conjugation, such as in the Crigler–Najjar syndrome. In
adults, the average total plasma UCB concentration is <20μM.
This value is higher in newborns, due to the immaturity of trans-
port and metabolic processes in the liver, which is faced with a
higher production rate. This typically results in a mild “physi-
ological” neonatal jaundice (UCB concentrations up to 170μM),
which is not harmful tonewborns andmay evenbebeneﬁcial to the
organism owing to the antioxidant properties of the pigment (for
review, see Jansen, 1999;Wennberg et al., 2009).When serum con-
centrations increase further,UCBmay become neurotoxic, leading
to clinical manifestations of encephalopathy, sometimes resulting
in irreversible brain damage when jaundice is especially severe or
prolonged (Jansen, 1999; Wennberg et al., 2009).
The prevalent explanation for the existence of a sharp thresh-
old plasma concentration of UCB setting its neurotoxicity is based
on the ability of UCB to bind with a high afﬁnity to plasma
proteins,mostly to albumin. The slowdissociation rate of the albu-
min/bilirubin complex and the short transit time of plasma in the
brain do not favor the cerebral penetration of bound UCB (Robin-
son and Rapoport, 1986). Numerous early works (reviewed in
Wennberg, 2000) demonstrated experimentally that the pigment
accumulates into the brain and neurotoxicity occurs when the
circulating free (unbound) UCB increases abnormally. This hap-
pens especially when plasma protein binding to UCB approaches
saturation, or when UCB is dissociated from albumin by drugs
competing for albumin binding sites. UCB is a dicarboxylic acid
which has remarkably high pK a values (8.1 and 8.4), and is thus
mostly non-ionized at the physiological plasma pH of 7.4. The
relative hydrophobicity of UCB allows it to readily permeate the
cell layers that form the tight blood–brain interfaces (BBIs) by
passive diffusion (Zucker et al., 1999; Vitek and Ostrow, 2009).
Within the brain some regions (mainly the basal ganglia, selected
brain stem areas, hippocampus, and cerebellum) show a greater
sensitivity to UCB toxicity (Shapiro, 2010). UCB alters neuronal
cell functions and causes cell death by mechanisms that seem
to involve synaptic dysfunction, but also oxidative stress, impair-
ment of mitochondrial oxidative phosphorylation and apoptosis
(reviewed in Watchko, 2006). In this pathophysiological scheme,
BBIs merely acts as structural barriers limiting the penetration of
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the carrier protein,while allowing unrestricted passive diffusion of
free UCB into the brain, and neural cells are considered as passive
targets of UCB toxicity.
Yet, our current knowledge on transport and metabolic
processes in the brain supports the concepts that (1) the impli-
cation of BBIs in the occurrence of bilirubin encephalopathy is
more complex than a simple role as a diffusion barrier to car-
rier proteins, and (2) neural cells such as astrocytes and neurons
appear to play an active role in controlling the balance between
the neuroprotective and neurotoxic properties of UCB.
Relevant to the ﬁrst point, BBIs may actively participate in the
regulation of the cerebral bioavailability of UCB. First, the bind-
ing afﬁnity of UCB to human serum albumin has been shown to
be strongly inﬂuenced by both albumin and chloride concentra-
tions and free UCB concentration is actually much higher than
previously thought (Weisiger et al., 2001). This suggests that para-
meters other than the rate of diffusional inﬂux of UCB exist at
the BBIs to account for the very low physiological UCB intrac-
erebral concentrations (Daood and Watchko, 2006; Zelenka et al.,
2008) and the absence of neurotoxicity. Furthermore, the numer-
ous transporters anddetoxifying enzymes that have beendescribed
in BBIs may confer an active role to the barriers in limiting the
entry of free UCB into the CNS, and/or in increasing its elimi-
nation from the CNS. In line with this latter possibility, Levine
et al. (1985) reported that bilirubin efﬂux from brain and cere-
brospinal ﬂuid (CSF) was an important factor of UCB cerebral
homeostasis. An alteration of the neuroprotective functions of
the BBIs is another aspect that may have been overlooked in
bilirubin-induced encephalopathy. The BBIs are key elements in
establishing the cerebral homeostasis required for proper brain
development and neuronal function throughout life. In addi-
tion to supplying the brain with nutrients and micronutrients
(Davson and Segal, 1996; Redzic and Segal, 2004), the BBIs protect
the cerebral tissue by decreasing brain exposition to numerous
circulating drug and toxic substances, and by their antioxidant
properties. The cells forming the BBIs are the ﬁrst cerebral cells
exposed to plasma free UCB, so that any impairment of their
antioxidant and neuroprotective functions, especially during the
postnatal period when the developing neuropil is highly sensi-
tive to toxic insults, may contribute to the occurrence of bilirubin
encephalopathy.
Relevant to the second point,UCB is present in the brain under
normal conditions at nanomolar concentrations (40–50 nM in
normobilirubinemic rats). UCB confers neuroprotection against
oxidative stress to cultured neuronal cells at similar (20–50 nM)
concentrations (Doré and Snyder, 1999), and become toxic for
neuronal cells at extracellular concentrations only slightly higher
(Ostrow et al., 1994). Physiologically, the main fraction of cere-
bral UCB derives from the peripheral degradation of hemoglobin,
but the pigment is also produced within the brain by catabolism
of other heme-containing proteins. Neural cells seem to possess
a biochemical machinery to maintain the intracellular concentra-
tion of UCB within a range compatible with the beneﬁcial effect
of the pigment, and damage occurs only when these mechanisms
are overrun by elevated UCB brain extracellular concentrations
such as during chronic unconjugated hyperbilirubinemia. In this
situation, the brain UCB content increases to micromolar levels
throughout the brain as shown in animal models (Zelenka et al.,
2008; Gazzin et al., 2012) while neuronal damage occurs with a
selective topography (Shapiro, 2010; Gazzin et al., 2012). This sug-
gests that factors other than intracerebral UCB concentration are
involved in the regional selectivity of UCB toxicity.
The following sections review these complex facets of bilirubin
interactions with the BBIs as well as with glial and neuronal cells
(Figure 1). They raise some questions that still need to be solved
in view to optimize the development of efﬁcient prophylactic and
therapeutic treatments to protect the brain against the accumula-
tion of excessive levels of UCB and prevent the neurotoxic effect
of the pigment.
BILIRUBIN INTERACTIONS WITH METABOLIC/TRANSPORT
PROCESSES AT THE BLOOD–BRAIN INTERFACES
SPECIFIC PROPERTIES OF THE BLOOD–BRAIN AND
BLOOD–CEREBROSPINAL FLUID BARRIERS
TheBBIs, togetherwith theCSF circulatory system,are responsible
for the homeostasis of the cerebral extracellular ﬂuid necessary to
neuronal functions. The interface between the blood and the brain
parenchyma proper, referred to as the blood–brain barrier (BBB),
is located at the endothelium of the cerebral microvessels. Peri-
cytes ensheathed in the endothelial basalmembrane and astrocytic
end-feet apposed to this membrane are thought to be essential for
the induction of the barrier phenotype characteristic of the brain
endothelium.Occasionalmacrophages are also associatedwith the
vasculature. Another barrier component is the blood–CSF barrier
(BCSFB), formed by the epithelium of the four choroid plexuses
(CPs; Figure 1). Located in brain ventricles, the CPs display the
highest local blood ﬂow rate among all cerebral structures, and
are responsible for the secretion of CSF. The CP–CSF system adds
a degree of complexity to the mechanisms that set the cerebral
bioavailability of both endogenous and exogenous bioactive com-
pounds. The CSF circulatory pathways, the precise histological
organization of these barriers and the interplay between the BBB,
BCSFB, and CSF have been described elsewhere (Strazielle and
Ghersi-Egea, 2000a; Ghersi-Egea et al., 2009a,b).
The molecular mechanisms that support the neuroprotective
functions of BBIs are multiple. The tight junctions efﬁciently
restrict the entry of blood-borne polar compounds into the brain,
with the exception of nutrients, polypeptides, and hormones
required for brain function, that are carried by selective inﬂux
transport systems. The penetration of more lipid-soluble mole-
cules capable of diffusing across the cell membranes is limited
by binding to serum albumin and inﬂuenced by transport pro-
teins present in both barriers. These transport systems include
P-glycoprotein, Breast Cancer Resistance Protein, or Multidrug-
associated Resistance Proteins (MRPs)1, all belonging to several
subfamilies of ATP Binding Cassette (ABC) efﬂux transporters.
They are also organic anion and cation transporters of the Solute
Carrier (SLC) superfamily. All these systems display broad sub-
strate speciﬁcities, and a pattern of expression speciﬁc to each bar-
rier. Being distributed between the blood-facing and brain-facing
1Capitalized characters are used when referring to human transporters and enzymes
or to transporters and enzymes listed in a general context. Minor characters are used
when speciﬁcally referring to rat or mouse transporters.
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FIGURE 1 | Cellular effectors involved in the bioavailability and
toxicity of UCB. Bilirubin exchanges between blood and brain occur
mainly across the microvessel walls forming the blood–brain barrier
(BBB) or the choroid plexus epithelium forming the
blood–cerebrospinal ﬂuid barrier (BCSFB). The cells forming these
barriers are sealed by tight junctions (black dots and lines). The
fenestrated choroidal vessels allow extensive exchanges between the
blood and the choroidal stroma. CSF–brain exchanges take place
across the ependyma, or the pia–glia limitans (not shown here).
Within the neuropil, neurons are the terminal target of bilirubin
toxicity. Astrocytes, microglia, and oligodendrocytes all play a role in
controlling bilirubin toxicity-over-beneﬁt balance.
membranes in both endothelial and epithelial cells, they work
in concert to achieve highly efﬁcient neuroprotection (Strazielle
et al., 2004; Leslie et al., 2005; Strazielle and Ghersi-Egea, 2005;
Gazzin et al., 2008). Finally, detoxifying enzymes present at BBIs
can inﬂuence the cerebral availability of toxic compounds (Ghersi-
Egea et al., 1994; Dauchy et al., 2008). In particular, CPs possess
a high conjugation capacity based on phase II drug metaboliz-
ing enzymes such as glutathione-S-transferases, as well as a high
epoxide hydrolase activity and antioxidant capacity, hence fulﬁll-
ing“liver-like” functions within the brain (Ghersi-Egea et al., 1995,
2006; Strazielle et al., 2004).
Within the CNS, diffusion between the CSF and the
parenchyma occurs more freely across the ependyma bordering
the ventricles, or the pia–glia limitans separating the neurons
from the subarachnoid and cisternal spaces as the cells form-
ing these interfaces are not linked by tight junctions. However,
exchanges between the different CNS compartments may be inﬂu-
enced by glutathione-S-transferases and ABC transporters, which
have been described in the ependymal and glial cells (Strazielle
and Ghersi-Egea, 2000b; Mercier et al., 2004; see infra).
The structural features of the barriers are established early on
during brain development. The paracellular pathway is already
impeded in the fetal brain, pointing to the efﬁciency of the BBIs in
protecting the developing brain. In addition the BBIs may fulﬁll
fence and transport functions which are speciﬁc to the immature
brain (Ek et al., 2006; Johansson et al., 2008;Daneman et al., 2010).
Less is known about the developmental regulation of the efﬂux
transporters and enzymes involved in detoxiﬁcation processes (see
infra).
It is well established that in the liver a complex interplay
between ABC efﬂux pumps, detoxifying enzymes, and possibly
SLC transporters (Table 1) allows controlling the plasma UCB
level. Similar interactions between UCB and these families of
proteins may occur at the BBIs, hence inﬂuence UCB cerebral
bioavailability.
MECHANISMS CONTROLLING BILIRUBIN PERMEABILITY AT BBIs
Transporters
Different studies (reviewed in Ghersi-Egea et al., 2009a) pointed
out UCB as a substrate for various transporters. These include
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Table 1 | Main potential mechanisms involved in bilirubin detoxification and elimination.
Binding (diminishes free fraction of UCB
in cytosol)
Bilirubin binds to glutathione-S-transferases. Alpha class subunits display the highest afﬁnity for UCB
Metabolism UCB is conjugated to glucuronic acid. This is catalyzed by UDP-glucuronosyltransferase UGT1A1
Bilirubin is oxidized by cytochrome-P-450-dependent monooxygenases (CYP1A1, CYP1A2, CYP2A5
(Cyp2a3 in rodents) isoenzymes)
Cellular export UCB is a high afﬁnity substrate for MRP1 (ABCC1)
UCB is a potential substrate for P-glycoprotein (ABCB1)
Bilirubin glucuronoconjugates are exported by several members of the ABCC family, such as ABCC2 and
ABCC3, and with less afﬁnity ABCC11
Cellular uptake (allows further metabolism
or elimination)
UCB can enter some polarized cells by a carrier-mediated process, possibly involving SLC21 (OATP)
transporters
Modiﬁed from Ghersi-Egea et al. (2009a).
the ATP-dependent ABCC1 transporter which is a member of
the multidrug-resistance associated protein family also called
MRP1, the ATP-dependent multidrug-resistance protein ABCB1
(human)/Abcb1a/b(rodents; see text footnote 1) also called P-
glycoprotein or MDR1,which displays a lower afﬁnity than MRP1,
and ﬁnally transporters of the SLC21/Organic Anion Trans-
port Polypeptide (OATP) family2, such as OATP1B3 (also called
OATP8, SLC21A8), or OATP1B1 (OATP-C, OATP2, SLC21A6) in
human.
P-glycoprotein and MRP1 are two major efﬂux transporters
involved in neuroprotection. They prevent access to, or increase
elimination from the brain of various endo- and xenobiotics
(Schinkel et al., 1996; Wijnholds et al., 2000; Schinkel and Jonker,
2003). P-glycoprotein is almost exclusively located at the blood-
facing luminal membrane of the endothelium forming the BBB,
while MRP1 is mainly located at the basolateral membrane of the
choroidal epithelium. This mirror image of the relative abundance
of P-glycoprotein and MRP1 between the two interfaces was con-
ﬁrmed in human (Gazzin et al., 2008). Different members of the
OATP family have also been localized at the BBB and BCSFB in
both laboratory animals and human. For most of these OATPs, the
precise cellular localization, directionality of transport and func-
tional signiﬁcance remain to be assessed (for details, see Strazielle
et al., 2004; Strazielle and Ghersi-Egea, 2005; Ghersi-Egea et al.,
2009a). OATP1A2 can transport opioid peptides across the human
BBB (Gao et al., 2000; Lee et al., 2005), and at the BCSFB,Oatp1a5
(Oatp3, Slc21a7) located at the apical membranes of the rodent
choroidal epithelium, transports organic anions from the CSF into
the choroidal epithelial cells, for further efﬂux into the blood.All P-
glycoprotein, MRP1, and those of the OATP transporters located
at brain-facing membranes, are ideally localized to prevent the
entry of blood-borne substrates, including UCB into the brain, or
to allow their elimination from the central nervous system.
In line with this hypothesis, a role of P-glycoprotein in
decreasing UCB penetration into the brain has been high-
lighted in Abcb1a/b knockout mice which display a cerebral UCB
2See Hagenbuch and Meier (2004) for review on new and old protein and gene
OATP nomenclatures.
concentration 1.8-fold higher than wild type animals after a 5-min
intravenous UCB infusion. Importantly, this treatment resulted
in a high plasma total UCB that was not different between the
two types of animals (Watchko et al., 1998). Brain-to-plasma
bilirubin ratios were also increased in wild type rats treated with
P-glycoprotein inhibitors (Hanko et al., 2003). The signiﬁcance
of a P-glycoprotein-dependent efﬂux process limiting free UCB
diffusion from plasma into the neuropil remains to be assessed
at lower clinically relevant UCB concentrations and in the devel-
oping brain. Indeed, a role for P-glycoprotein in the canalicular
efﬂux of UCB in the liver could not be established, and the amount
of P-glycoprotein associated to microvessels isolated from 9-day-
old animals is only one-ﬁfth of that measured in capillaries from
adult animals (Gazzin et al., 2008). No study has speciﬁcally inves-
tigated the involvement of MRP1 in UCB transport across the
BCSFB. A considerable uptake of UCB by isolated rabbit CP has
been described, which is inhibited by iodipamide, a substrate of
organic anion transport systems (Jakobson, 1991). Which OATP
or other transport proteins located at the brain-facing membranes
of the BCSFB are involved in the clearance of UCB from the CNS
remains an open question. It is however tempting to hypothesize
that the carrier-mediated uptake of UCB at the apical membrane
of the choroidal epithelium, coupled to active efﬂux into the blood
via the basolateral MRP1 pump forms a pathway accelerating the
clearance of UCB from theCNS. Suchmechanismwould be of spe-
cial interest during early postnatal life, as theCP is a brain structure
maturing early during development, and already expresses high
levels of MRP1 at birth (Gazzin et al., 2008; Johansson et al., 2008).
Metabolizing enzymes
In the liver, UCB interacts mainly with three families of detox-
ifying enzymes, cytochrome P-450-dependent mixed function
oxygenases (CYPs), glutathione-S-transferases (GSTs), and UDP-
glucuronosyltransferases (UGTs).
Unconjugated bilirubin taken up by hepatocytes binds to
cytosolic isoforms of GST, which act as a sink that maintains the
gradient of free UCB and limits its backﬂux into plasma. There are
several GST classes, those best characterized in mammals being
the alpha, mu, and pi classes (see Mannervik et al., 2005 for GST
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nomenclature in human, rat, and mouse). GSTs are homo- or
heterodimer proteins. The GSTA (alpha class) subunits have the
highest afﬁnity for free UCB. Dimers of GSTA1 and/or GSTA2
form ligandin, the main GST isoform involved in hepatic UCB
binding. This binding is independent of the enzymatic activity
(bilirubin is not conjugated to glutathione), and contributes to
protect the cells by maintaining the intracellular pool of free UCB
at low level. Itmay also facilitateUCB transfer to the smooth endo-
plasmic reticulum for further catabolism. The three main classes
of cytosolic GSTs of all three alpha, mu, and pi classes are present
in BBIs, although GST pi rather than GST alpha seems to be the
major GST proteins in adult human brain capillaries (Shawahna
et al., 2011). GST-dependent activities are especially high in CPs
isolated from both animal and human developing brain (reviewed
in Ghersi-Egea et al., 2006, 2009a). Thus, in the course of UCB
transport across BBI cells, binding of UCB to GST subunits, espe-
cially of the alpha class,may contribute to an overall barrier effect.
The developmental proﬁle of GST proteins at the interfaces dif-
fers between the pi, mu, and alpha classes. In rat, transcripts of
mu and pi subunits are higher in CPs from newborn compared
to adult animals, while those of the alpha subunits which dis-
play the highest afﬁnity for UCB are absent or down regulated in
newborn pups (unpublished data). The alpha class subunits were
detectable by immunohistochemistry only 10 days after birth in
mouse choroidal cells (Beiswanger et al., 1995), or in adult but not
fetal CP in human (Carder et al., 1990). Hence, at CSF-contacting
interfaces,UCB binding toGST subunits is likely to be less efﬁcient
during development than at the adult stage.
Bilirubin metabolic pathways include oxidation by CYPs,
namely CYP1A1 and CYP1A2 (Kapitulnik and Gonzalez, 1993), as
well as CYP2A5 (Abu-Bakar et al., 2005; Cyp2a3 in rodents). Activ-
ities of CYP isoenzymes appear modest in cells forming the BBIs
(Strazielle and Ghersi-Egea, 2000b; Miksys and Tyndale, 2002).
Total cytochrome P-450 has been detected by spectrophotometry
in microvessels isolated from both rat and human brains (Ghersi-
Egea et al., 1993). Gene and protein expression studies con-
ducted in human microvessels showed that CYP1B1 was the main
endothelial CYP, while CYP1A1 and 2 expression levels were low
or undetected (Dauchy et al., 2008; Shawahna et al., 2011). Cyp1a1
protein has been detected in cultured mouse brain endothe-
lial cells only after treatment with 2,3,7,8-tetrachlorodibenzo-p-
dioxin, an inducer acting via the Ah receptor (Filbrandt et al.,
2004). Cyp1a1 mRNA was detected in isolated rat capillaries only
following in vivo treatment with Ah receptor-dependent induc-
ers but the Cyp1a1 protein was not detected (Jacob et al., 2011).
Another study performed by Western blot detected the protein in
brain microvessels following Ah receptor activation (Wang et al.,
2011). This apparent discrepancy may have come from differ-
ences in the composition of themicrovessels preparations between
the two studies. Indeed previous in vivo works had shown that
Cyp1a1 was detected in mouse cerebral veins rather than capil-
laries following treatment with Ah receptor-dependent inducers.
Induced Cyp1a1 was also detected in rat and mouse choroidal
sinusoidal vessels (Brittebo, 1994; Morse et al., 1998; Dey et al.,
1999; Granberg et al., 2003). No information is available concern-
ing CYP2A5 in brain barriers. Overall, CYP activities likely play
only a minor role in UCB metabolism at BBIs, unless speciﬁc
inductive mechanisms occur in the course of hyperbilirubinemia
(see infra).
The main pathway of bilirubin detoxiﬁcation in the liver is
conjugation with glucuronic acid. It is speciﬁcally catalyzed by
the UGT1A1 isoenzyme (Kadakol et al., 2000). This pathway
leads to the production of the more water soluble mono and di-
glucuronide metabolites which are mainly transported from the
liver into the bile by ABCC1, 2, and 3 proteins (Keppler, 2011).
In the rat brain, Ugt activity toward planar compounds is sev-
eral times higher in microvessels than in the cerebral parenchyma,
and is notably comparable to the hepatic activity in the choroidal
epithelium, even in developing animals (Ghersi-Egea et al., 1994;
Strazielle and Ghersi-Egea, 1999). In both barriers these activi-
ties increase following in vivo treatment of rats with exogenous
inducers (Ghersi-Egea et al., 1988; Leininger-Muller et al., 1994).
The UGT isoenzyme responsible in rat BBIs for the conjugation of
planar compounds is likely to be Ugt1a6 (Gradinaru et al., 2009).
Ugt1a1mRNAhas been reported inwhole rat brain extract (Shelby
et al., 2003), but it is not known whether Ugt1a1 is associated
with BBIs in rodents. Neither UGT1A6 nor UGT1A1 mRNA was
detected in human brain capillaries (Shawahna et al., 2011). As
the CPs fulﬁll “liver-like” functions for the brain, and as the con-
jugation to glucuronic acid within the epithelial cells, coupled to a
basolateral efﬂux of the resulting glucuronides forms a functional
metabolic barrier preventing the entry of selected substrates into
the CSF (Strazielle and Ghersi-Egea, 1999), the choroidal tissue
might prove to be an important site of UCB detoxiﬁcation in the
brain. This and the presence of different ABCC proteins located in
both brains barriers (reviewed inGhersi-Egea et al., 2009a), call for
more investigations on UCB and bilirubin conjugate disposition
at the BBIs.
CSF proteins
The protein concentration is of 3.2 g/l in CSF at birth in rat and
decreases thereafter to reach adult values as low as 200mg/l. This
is not due to an immaturity of the BBIs allowing non-speciﬁc
leakage of plasma proteins into the brain, but rather to a regu-
lated mechanism involving a specialized transport function of the
BCSFB during development (Johansson et al., 2008). This opens
new ﬁelds of investigation to appreciate the relevance of CSF and
ICF proteins in sequestering UCB within the extracellular space in
the brain during early postnatal development, and to decipher the
choroidal mechanisms that control protein CSF concentration in
normal and jaundiced brain.
Photoisomers
Finally, the BBIs may play a signiﬁcant role in the mechanisms
behind the efﬁcacy of phototherapy, a treatment degrading the
light sensitive plasma UCB in jaundiced children. During pho-
totherapy, both photooxidation and photoisomerization of UCB
occur. While the former is a slow process, photoisomers are
detected in blood within minutes after starting the treatment, and
although the reaction is reversible, the major 4Z, 15E photoiso-
mer represents 20–30% of total bilirubin after 2 h. Total bilirubin
concentration is not affected as rapidly in cases of phototherapy in
jaundiced newborn, and does not decrease in blood during the 4-h
following treatment initiation (Mreihil et al., 2010). Yet, because
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the isomers have lower lipid solubility relative to the parent UCB
species, and should be restricted to a greater extent by the BBIs, an
immediate phototherapy beneﬁt should be achieved before UCB
plasma levels are normalized.This hypothesis remains tobeproven
experimentally (McDonagh, 2010).
ALTERATION OF THE NEUROPROTECTIVE FUNCTIONS OF BBIs BY
HYPERBILIRUBINEMIA
At low concentration UCB behaves as an antioxidant agent and
may represent a transitional antioxidative mechanism during
physiological jaundice (see infra). However, higher concentra-
tions of bilirubin are harmful. In vitro studies have shown that
a prolonged exposure of cells to free bilirubin at concentrations
that were within the range of aqueous solubility, i.e., similar to
plasma free bilirubin concentrations reached in moderate jaun-
dice,elicited cytotoxic effects towarddifferent cell types (Chuniaud
et al., 1996 and reviewed in Ostrow et al., 2002). The molec-
ular mechanisms of UCB cytotoxicity, assessed mostly in vitro,
are not fully unraveled. Besides neuron-speciﬁc mechanisms, key
events in UCB-induced toxicity would involve both oxidative
injury and mitochondrial damage. The latter is probably trig-
gered by bilirubin-membrane interactions and leads to an impair-
ment of oxidative phosphorylation (reviewed in Watchko, 2006;
Ghersi-Egea et al., 2009a).
This mechanism is especially relevant when evaluating the
role of BBIs in bilirubin cerebral toxicity, because the cells form-
ing the BBIs are the ﬁrst cerebral cells exposed to blood-borne
free bilirubin, and many of the key functions of the barriers are
energy-dependent. Mitochondria are numerous in cells forming
the BBIs, especially the choroidal epithelial cells (Schlosshauer,
1993; Cornford et al., 1997). Tight junction protein complexes
undergo continuous molecular remodeling, which is linked to
the energy status of the cells (Eckert and Fleming, 2008; Shen
et al., 2008). ABC efﬂux transporters involved in neuroprotection
are unidirectional, and require ATP-dependent energy to trans-
port substrates against the concentration gradient. Several other
organic anion and cation transporters are secondarily dependent
on inorganic anion gradients generated by the Na+K+ATPase, as
demonstrated at the BCSFB (Pritchard et al., 1999). Finally, at
the CP, CSF secretion is also a tightly controlled process linked to
Na+K+ATPase.
These different BBI-related neuroprotective mechanisms have
hardly been evaluated in the context of bilirubin encephalopathy.
Experimental hyperbilirubinemia obtained by short-term contin-
uous infusion of bilirubin does not lead to any prominent alter-
ation of the barrier integrity (Roger et al., 1993, 1995). Alterations
secondary to mitochondrial dysfunction are likely to develop only
after sustained exposure to elevated levels of UCB. Accordingly,
a decrease in the expression of occludin, one of the proteins
forming the tight junctions in BBB and BCSFB, was observed
in microvessel fractions prepared from brains of rats subjected
to obstructive jaundice for several days. The direct involvement
of bilirubin in this process was however not evaluated (Faropou-
los et al., 2010). Exposition of bovine brain endothelial cells in
culture to UCB concentrations generating high levels of extracel-
lular free bilirubin-induced cell apoptosis (Akin et al., 2002). A
similar increase in apoptotic/necrotic processes was more recently
described in an immortalized cell line and in primary cultures
of human brain endothelial cells exposed for several hours to
lower and more physiopathologically relevant free bilirubin con-
centrations (Palmela et al., 2011). In this study, the cell loss in
bilirubin-treated cultures was twice that in untreated cells after
24 h. The relevance of these in vitro data to in vivo UCB–induced
brain endothelial cell lethality remains to be established. In these
cells, bilirubin only marginally affected inﬂammatory mediators,
and induced an oxidative stress reﬂected by a large increase in
nitrite production by comparison with untreated cells. The effect
of such UCB-induced alteration of the redox status on the barrier
properties of the endothelial cell monolayers was not assessed. The
potential inﬂuence of bilirubin-activated perivascular astrocytes
and macrophages on BBB properties would also deserve attention.
The effect of UCB on the BCSFB has been investigated using
monolayers of rat choroidal epithelial cells cultured in bicam-
eral devices that maintain the barrier and transport properties
of this barrier (Strazielle and Ghersi-Egea, 1999; Strazielle and
Preston, 2003; Ghersi-Egea et al., 2006). The cells were exposed
at their basolateral (blood-side) membrane to 40 and 140 nM
free bilirubin, concentrations respectively below and above the
aqueous solubility of the pigment and which mimic levels eval-
uated in physiological and pathological jaundices, respectively
(Rigato et al., 2005; Ahlfors et al., 2009). Treatment was applied
for six consecutive days to approach the in vivo prolonged post-
natal exposure. This treatment did not alter the integrity of the
barrier, as assessed by the measurement of the paracellular per-
meability of the monolayers to sucrose (Gazzin et al., 2011).
The high antioxidant capacity of the choroidal tissue (Tayarani
et al., 1989; Ghersi-Egea et al., 2006), in concert with efﬂux trans-
porters, may allow maintaining the integrity of the barrier under
pathophysiologically relevant UCB-challenge.
By contrast, ABC transporters are affected by sustained UCB
exposure. The homozygous hyperbilirubinemic jj Gunn rat
bears a congenital inherited deﬁciency of the hepatic UDP-
glucuronosyltransferase enzyme and is used as an animal model
of Crigler–Najjar type I syndrome and neonatal jaundice. P-
glycoprotein expression is increased up to twofold in brain
microvessels from developing jj Gunn rats as compared to het-
erozygous littermates; however, it does not reach the high levels
observed in microvessels of adult animals. More strikingly, the
level of MRP1 protein, already high in CPs of newborn animals,
is decreased by 50% in jj Gunn rats compared to heterozygous
littermates. This decrease in protein content was a direct effect
of bilirubin, because it could be reproduced by treating choroidal
epithelial cells for 6 days with UCB at a dose generating a 140-
nM free bilirubin concentration in the medium (Gazzin et al.,
2011), the latter concentration mimicking the levels measured
in pathological jaundice in Gunn rats 9 days after birth (Gazzin
et al., personal communication). Mrp1 is involved in regulating
the cerebral availability of endogenous biologically active com-
pounds and of circulating potentially toxic xenobiotics. Hence the
UCB-induced decrease in the efﬂux transport activity of choroidal
MRP1 may critically impact on normal brain maturation.
Finally, the CPs strongly participate to thyroid hormone home-
ostasis which is crucial for brain maturation (reviewed in Zheng,
2001; Ghersi-Egea et al., 2009a). UCB competitively inhibits
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cellular uptake of thyroid hormones in hepatocytes (Lim et al.,
1993; Hennemann et al., 2001). Whether hyperbilirubinemia also
disturbs cerebral thyroid hormone transport and homeostasis
needs to be assessed in jaundiced neonates.
CONTROL OF BILIRUBIN INTRACELLULAR CONCENTRATION
AND TOXICITY IN THE NEUROPIL
ANTIOXIDANT FUNCTION OF BILIRUBIN: THE BILIVERDIN/BILIRUBIN
REDOX CYCLE IN NEURAL CELLS
Among all body organs, the brain shows the highest rate of oxy-
gen metabolism, consuming 20% of the whole body oxygen while
weighting only 2% of the total body (Clarke and Sokoloff, 1999).
Oxygen reactive species (ROS) are continuously generated at a
high rate, and oxidative stress does occur to a certain degree in the
absence of any pathology. ROSmay damage sugars,proteins,DNA,
and lipids. The brain is rich in unsaturated fatty acids which are
main targets for lipid peroxidation. Relevant to perinatal diseases,
birth is accompanied by a sudden exposition to oxygen, leading to
an increased oxidative stress. In premature newborns, antioxidant
defenses are not fully efﬁcient because their maturation occurs
during the late gestation period (Saugstad, 1989; Friel et al., 2004).
Thus newborns and especially premature infants exhibit a unique
sensitivity to oxidant injury.
The brain possesses only moderate antioxidant superoxide dis-
mutase and glutathione peroxidase activities compared to the
liver (Cooper et al., 1997; Ho et al., 1997), with the exception of
the CP (Tayarani et al., 1989). Besides the reduced/oxidized glu-
tathione redox cycle functioning as a cell antioxidant mechanism,
the bilirubin-dependent redox cycle also seems to play a role in
cell protection against oxidative stress in brain, for the following
reasons.
Bilirubin is present in brain tissue under normal conditions
in nanomolar concentrations (20–50 nM; Gazzin et al., 2012).
The dynamic of bilirubin movement between extracellular and
intracellular compartment is complex, and may involve both
transporter-mediated processes and diffusion.Hence data onUCB
concentration in tissue do not inform on the actual intracellular
concentration in different neural cells. Bilirubin concentrations
in the overall brain represent less than 0.1% of the level of the
antioxidant molecule glutathione (Baranano et al., 2002). Nev-
ertheless the pigment ability to protect against oxidative stress
is well acknowledged (Dennery et al., 1995; Dohi et al., 2005;
Vitek, 2005a,b), and evidence that this holds true for brain cells
has been documented. Bilirubin is the reduction product of
biliverdin. The biliverdin/bilirubin and glutathione redox cycles
share some similarities. Biliverdin synthesis results from the degra-
dation of heme-containing proteins by heme oxygenases (HO).
The inducible HO-1 is expressed in glial cells (Dwyer et al., 1995)
and is induced by oxidative stress (Calabrese et al., 2006). The
constitutive HO-2 accounts for the main portion of this enzy-
matic activity in brain, where it seems to be expressed in neuronal
populations in several regions (Ewing and Maines, 1997; Man-
cuso, 2004). HO-2 impairment results in a loss of bilirubin in
cells and a higher susceptibility to different CNS damages (Chen
et al., 2005). Doré et al. (1999) described a correlation between
an activation of HO-2 by protein kinase C-mediated phosphory-
lation, increased cellular bilirubin levels (sixfolds after 24 h), and
resistance to H2O2 induced stress in cultured hippocampal and
cortex neurons.
Biliverdin is reduced to bilirubin by the cytosolic enzyme
biliverdin reductase (BVR), the depletion of which strongly
induces (20–40%) the apoptosis of cells cultured from hippocam-
pal/cortical structures (Sedlak et al., 2009). BVR activity requires
free SH groups and NADH or NADPH (at pH of 6.8 and 8.7,
respectively; Maines and Trakshel, 1993). BVR pattern of expres-
sion in normal brain coincides with HO gene expression (Ewing
et al., 1993). BVR is also involved in cell signaling (Kapitulnik
and Maines, 2009), and can transport the transcription factor
hematin from the cytoplasm to the nucleus, thereby allowing
hematin-dependent HO-1 gene transcription (Tudor et al., 2008).
Silencing BVR leads to a depletion of cellular bilirubin, increases
cellular ROS and promotes apoptotic death in neuronal cultures
(Baranano et al., 2002). Finally BVR can increase bilirubin pro-
duction from heme degradation during oxidative stress (Miralem
et al., 2005). In turn, the increase in UCB inhibits BVR and HO
activity, maintaining a balanced intracellular biliverdin/bilirubin
ratio (Maines, 2005). When produced intracellularly, bilirubin
may act asROS scavenger by quenching reactive radicals (Nag et al.,
2009) before being reoxidized to biliverdin (Baranano et al., 2002).
In brain homogenate, biliverdin, and bilirubin have been reported
to inhibit lipid peroxidation induced by hemoglobin. This was not
observed in vivo after intrastriatal injection of hemoglobin, prob-
ably because of its conversion into biliverdin and bilirubin by the
endogenous enzymatic machinery (Van Bergen et al., 1999).
Finally, approaches using bilirubin antioxidant properties for
therapeutic purposes have been evaluated experimentally. The
administration of exogenous biliverdin (immediately converting
into bilirubin) to rat following transient cerebral artery occlusion,
signiﬁcantly reduced the volume of infarct tissue as well as super-
oxide production and lipid peroxidation (Deguchi et al., 2008).
In autoimmune encephalomyelitis, an animal model for multiple
sclerosis, treatment with BVR (10μg/day) ameliorates the out-
come of the pathology more efﬁciently than optimal treatments
with catalase or HO-1, while treatments with superoxide dismu-
tase and glutathione reductase have no signiﬁcant effect (Liu et al.,
2006).
Overall, these sets of data indicate that biliverdin production
and the biliverdin/bilirubin cycle are effective in the brain, and can
play a role in the regulationof oxidative stress. The huge capacity of
bilirubin to protect against oxidative stress (10 nM UCB protects
against 75μMH2O2 in cell culture,Doré and Snyder, 1999), seems
to result from the high turn-over rate of the biliverdin/bilirubin
cycle (Baranano et al., 2002) by comparison to the glutathione
redox system (Hollensworth et al., 2000). The two redox sys-
tems appear complementary. Unlike glutathione, bilirubin binds
avidly to albumin and to cell membranes, especially myelin rich
membranes (Mustafa and King, 1970; Brodersen, 1981), where it
may prevent lipid peroxidation and protect the proteins inside the
bilayer (Van Bergen et al., 1999). Reduced glutathione and biliru-
bin have thus been hypothesized to be complementary in their
effects against oxidative stress. Reduced glutathione may serve as a
protectant for cytoplasmic ROS targets, while bilirubin acts pref-
erentially against lipid peroxidation. This was demonstrated in
cultured HEK293 cells (Sedlak et al., 2009). The sixfold increase in
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protein oxidation in H2O2 treated cells compared to control cells
was reversed by addition of reduced glutathione but not bilirubin,
while a 2.5- to 3-fold increase in lipid peroxidation was obtained
by silencing BVR activity, but not by BSO-induced glutathione
depletion. A conﬁrmation of this hypothesis was obtained in vivo
by comparing wild type and HO-2 deleted mice (Sedlak et al.,
2009).
Besides complementing each other, the glutathione redox cycle
and the biliverdin/bilirubin cycle undergo complex interactions.
Ononehand, the reduced/oxidized glutathione equilibriumacts as
a sensor for redox stress. Reduced glutathione depletion activates
HO-1 gene transcription, probably by mitogen-activated protein
kinases, and thereby could favor the bilirubin/biliverdin cycle. On
the other hand, molecules bearing free thiol groups are necessary
to BVR activity. Thus a decrease in the concentration of reduced
glutathione and other molecules bearing SH groups might impact
on the efﬁcacy of the bilirubin/biliverdin cycle.
A threshold UCB concentration sets the switch between anti-
and pro-oxidant effects of bilirubin. Doré and Snyder (1999)
reported that its maximal neuroprotective effects in hippocampal
cultures was reached at nanomolar concentrations (10–50 nM),
while at higher pigment concentrations the pro-oxidant effects of
bilirubin started to dominate. A similar dual effect was reported in
primary cultures of oligodendrocytes (Liu et al., 2003). The exact
concentration thresholds between anti- and pro-oxidant effects of
bilirubin in different brain structures and cells in vivo are however
not well estimated, and need further investigation.
METABOLIC/TRANSPORT PROCESSES CONTROLLING BILIRUBIN
CONCENTRATION AND TOXICITY IN GLIAL AND NEURONAL CELLS
The pro-oxidant activity of UCB is probably the most studied
aspect of bilirubin encephalopathy and kernicterus in which UCB
content in tissue increases from protective nanomolar to toxic
micromolar concentrations,mainly as a result of UCB inﬂux from
blood (Zelenka et al., 2008;Gazzin et al., 2012).Neural cells possess
regulatory mechanisms that allow controlling UCB intracellular
concentrations to some extent. Even if expressed at lower levels
than in BBI (see supra), transporters, and detoxifying enzymes
such as those described in Table 1 might act also at the brain
parenchyma level.
Among the two ABC proteins that transport bilirubin, P-
glycoprotein level of expression is at least 20 times lower in whole
brain parenchyma compared to cerebral capillaries, indicating that
P-glycoprotein is almost exclusively located at the BBB (Gazzin
et al., 2008) and is unlikely to play a role in bilirubin transport
in neural cells. Of note, P-glycoprotein has been identiﬁed in cul-
tured microglia (Lee et al., 2001) and astrocytes (Ronaldson et al.,
2004). The high afﬁnity bilirubin transporter Mrp1 (Rigato et al.,
2004) is present in rat brain parenchyma, where the protein con-
tent represents 6% of that measured in the BCSFB (Gazzin et al.,
2008). Mrp1 is not enriched in the capillary fraction compared to
parenchyma, indicating its presence in neural cells. Accordingly, it
has been identiﬁed on brain tissue sections in rat astrocytes and in
the glia limitans (Mercier et al., 2004). In vitro, the expression of
MRP1 was shown in microglia primary cultures or cell lines (Dal-
las et al., 2003), in oligodendrocytes (Hirrlinger et al., 2002), and
in rat, mice, and human primary cultures of astrocytes (Decleves
et al., 2000; Hirrlinger et al., 2002, 2005; Spiegl-Kreinecker et al.,
2002; Gennuso et al., 2004; Falcão et al., 2007). The simultaneous
up-regulation and redistribution of the transporter from the per-
inuclear region to the plasma membrane after exposure to UCB
was interpreted as a mechanism to confer cellular protection by
allocating the UCB transporter in the most adequate subcellular
position to face pigment entry (Gennuso et al., 2004). Mrp1 was
also detected in primary cultures of embryonic rat neurons, even
if in amounts lower than in astrocytes (Falcão et al., 2007). An
inverse correlation between Mrp1 expression and sensibility to
UCB, was reported in neurons and astrocytes, possibly explaining
the higher UCB toxicity observed in cultured neurons which dis-
play the lowest levels of Mrp1 (Falcão et al., 2007). In agreement
with a protective function of MRP1, mouse embryonic ﬁbroblast
cells derived from Mrp1 KO mice (Calligaris et al., 2006), and SH-
SY5Y cells in which the transporter activity was silenced (Corich
et al., 2009), displayed a higher mortality after bilirubin treatment
compared to their respective controls. Cell culture conditions sub-
stantially modulate the expression of several ABCs transporters,
however, and the observations obtained from in vitro experiments
may not be fully applicable to the in vivo scenario. Accordingly,
the actual levels of expression and functional relevance of UCB
transporters in brain parenchyma in vivo are still debated.
The potential relationship between GST isoforms present in
astrocytes and bilirubin toxicity has not been investigated, but
in one study that showed higher cytosolic GST activity and
level of alpha class GST subunits in cerebellum of hyperbiliru-
binemic jj Gunn rats compared to the Jj heterozygous animals.
Within this distinct structure, the alterations in GST levels were
region-speciﬁc, developmentally regulated, and inversely related
to region-speciﬁc cerebellar hypoplasia (Johnson et al., 1993).
This calls for additional investigation on the potential implication
of GSTs in the control of long-term hyperbilirubinemic cerebral
intoxication.
CytochromeP-450monooxygenases are involved in controlling
bilirubin concentration in tissues and cells, as originally shown
by Kapitulnik and colleagues. Selected hepatic Cyps isoforms
(Cyp1a1 and 1a2) are able to compensate for the lack of hepatic
glucuronidation in Gunn rat (Kapitulnik et al., 1987; Kapitulnik
and Gonzalez, 1993), by increasing UCB body clearance follow-
ing its oxidation (Zaccaro et al., 2001; De Matteis et al., 2006).
CYP isoenzymes display a highly heterogeneous expression among
different regions or cellular types in the CNS. For instance it is pro-
posed that certain cellular subsets might express CYPs at levels as
high as in the liver (Chinta et al., 2005b). Thus, it is conceivable
that local CYP-dependent metabolic pathways have considerable
effects onbrainpathology andphysiology.CYP1A1and1A2 seems
to be largely expressed in brain, predominantly in cerebral cortical
neurons,Purkinje, and granule cells of hippocampus (Chinta et al.,
2005a). CYP1A2 pattern of expression in human brain seems to
be diffuse (Farin and Omiecinski, 1993). The role played by CYPs
in brain resistance to bilirubin has just started to be investigated.
The expression of CYPs was investigated in the context of typi-
cal kernicterus which occurs only when an acute shift of bilirubin
from blood to tissues is generated. It was reproduced experimen-
tally in homozygous Gunn rats exposed to sulfadimethoxine to
displace bilirubin from albumin. In this model, ABC proteins
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appear inefﬁcient to control the sudden increase in tissue free
bilirubin concentrations (Gazzin et al., 2012). By contrast, a strong
correlation was observed between the time-course and extent of
induction of the Cyp genes involved in bilirubin oxidation on one
hand, and the kinetic of tissue UCB disappearance on the other
hand, in the different brain regions. Cyp mRNAs increased up to
70-fold in some regions, but returned to basal levels within 48–
72 h, indicating that these changes are transitory. Overall, this set
of data points to the possible role of UCB-mediated CYP induc-
tion in limiting UCB accumulation in selected brain regions, and
suggests that these enzymes may protect selected brain areas from
bilirubin neurotoxicity (Gazzin et al., 2012).
UNDERSTANDING CELLULAR AND REGIONAL SELECTIVITY OF
BILIRUBIN TOXICITY
A decade ago, based on the observation that yellow staining of
the basal nuclei is an extremely rare event, even in newborns that
die from severe neonatal jaundice, Hansen challenged the con-
cept that hyperbilirubinemia always leads to kernicterus by UCB
accumulation in distinctive brain areas. In fact, only few cases
of “real kernicterus” strictly describing bilirubin accumulation in
speciﬁc brain regions have been reported in humans (Hansen,
2000). This conclusion was recently corroborated experimentally
using the Gunn rat as an animal model for this disease. Biliru-
bin concentrations measured in four different brain regions in
hyperbilirubinemic animals were found identical (Gazzin et al.,
2012). Along the same line, the local cerebral blood ﬂow that
could inﬂuence the net blood-to-brain UCB ﬂux is more homo-
geneous among regions in both human and rodent during early
postnatal development than in adult, and is not correlated to the
regional susceptibility to UCB toxicity (reviewed in Ghersi-Egea
et al., 2009a). Similarly P-glycoprotein-dependent efﬂux processes
which could marginally inﬂuence the net UCB ﬂux in brain struc-
tures (see supra) is rather homogeneous among brain regions at
least in the human adult (Eyal et al., 2010).
Despite the absence of a typical kernicterus, no doubt exists,
however, as to the localization of damage to speciﬁc brain struc-
tures in both the human pathology and its experimental models
(Shapiro, 2010). One hypothesis to explain this selective topog-
raphy of bilirubin-induced injury would be based on a superim-
posable selective regionalization of the threshold concentrations
between the anti- and pro-oxidant effects of the pigment.
Evidence for such a heterogenous sensitivity to bilirubin tox-
icity has already been reported between organs, regions within
a given organ, or cells types in the same region. In hyperbiliru-
binemic Gunn rats, the bilirubin content in organs involved in
heme metabolism such as the liver and spleen is several folds
higher than that determined in brain (Zelenka et al., 2008; Gazzin
et al., 2012), yet UCB-induced tissue damage has never been
reported in the formers. In the brain, UCB-induced toxicity leads
mainly to neuronal loss (especially Purkinje and granular cells
from cerebellum; Keino et al., 1985; Conlee and Shapiro, 1997)
and myelination defects (Brito et al., 2012). In line with this, astro-
cytes displayed a greater resistance than neurons to UCB toxicity
(Brito et al., 2008), and the myelin-forming oligodendrocytes and
their precursors have also emerged as possible sensitive targets in
bilirubin encephalopathy (Kapitulnik, 2004). The latter hypothesis
is corroborated by in vitro studies showing that oligodendrocyte
viability decreases after exposure to UCB (Genc et al., 2003). It is
in agreement with both the myelin alterations described in hyper-
bilirubinemic Gunn rats (O’Callaghan and Miller, 1985) and the
loss of myelin ﬁbers described in a preterm infant with kernicterus
(Brito et al., 2012). With respect to regional differences, when pri-
mary cultures of neurons isolated from the cerebral cortex, the
hippocampus or the cerebellum were exposed to UCB, hippocam-
pal cells presented more oxidative damage associated with lower
reduced glutathione levels, impairment of neurite outgrowth, and
maximal cell death compared with cerebellar and cortical neu-
rons (Vaz et al., 2011). This points to differences in the intrinsic
sensitivity to UCB between neuronal sub-populations.
Asbilirubindetoxiﬁcationmechanisms are inducible/repressible
processes, a differential modulation of transporters and enzymes
following exposure to UCB must also be considered when search-
ing for factors involved in the cell- and tissue-speciﬁc toxicity.
The initial data described above such as those obtained for ABC
transporters in the BBIs and neural cells, or for CYPs and GSTs in
the neuropil, support a link between the expression level of these
genes and bilirubin-induced toxicity, which needs to be further
investigated.
Finally, the vulnerability of the brain to UCB intoxication is
dependent on the timing of UCB exposure. The maximal sensi-
tivity is observed during early postnatal development (Rice and
Barone, 2000), at a time when the CNS undergoes extensive
remodeling andmaturationwith temporal differences between the
various cerebral structures. Thus the developmental age at the time
of insult may determine the neural cell sensitivity to UCB intox-
ication, and possibly the efﬁciency of neuroprotective pathways
in the different brain regions, and thereby inﬂuence the regional
pattern of damage.
FUTURE CHALLENGES
An in-depth characterization of the detoxiﬁcation and transport
processes at BBIs and in the different neural cells of the developing
brain are probably themost important basic knowledgewe need to
acquire inorder tobetter appreciate the functional basis of selective
brain structure damage following exposure to elevated UCB levels.
The phenotype, the magnitude of symptoms, and the outcome of
the disease vary with the developmental age at the time of biliru-
bin exposition. This heterogeneity thus calls for studies deﬁning
the developmental proﬁle of the various effector molecules. These
include all transporters and enzymes involved in UCB detoxiﬁca-
tion or in the regulation of CSF protein level and those exerting
neuroprotective functions (antioxidants). Furthermore, these key
actors should be investigated in the context of the pathology to
evaluate the possible UCB-induced alteration in their expression
or activity. Due to the complexity of the brain architecture and
the developmental pattern speciﬁc to each cerebral structure, it is
reasonable to speculate that several “sensible targets” are yet to be
identiﬁed, and that those targets are developmentally regulated.
From a therapeutic point of view, conventional treatments
include phototherapy and blood exchanges for hyperbilirubine-
mic infants, and liver transplantation or gene therapy for patients
with the Crigler–Najjar syndrome. While waiting for new ther-
apeutic targets to be identiﬁed, neuroprotective therapies that
complement the conventional treatments in their initiation phase
would be highly beneﬁcial to the ﬁnal outcome of the disease.
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A current approach is to target the perturbations of the neural
cell redox status. Minocycline, a drug with properties similar
to Vitamin E (Kraus et al., 2005), and already in use in sev-
eral other central nervous system disorders, inhibits the cerebellar
hypoplasia in Gunn rats (Lin et al., 2005). Unfortunately, its use
in bilirubin-induced neurological disorders is impeded by side
effects in pediatric patients (Yong et al., 2004). This highlights
the difﬁculty of developing therapeutic strategies for this category
of patients and stresses out the real need to fully understand the
differences between adult and children in the factors setting the
cerebral bioavailability of drugs, including drug transporters at
BBIs. Among milder therapeutic approaches, essential fatty acid
supply may be considered. Polyunsaturated fatty acids are major
components of brain membranes and especially of myelin, and
fatty acid depletion impairs nervous system functions leading to
learning, motor, vision, and auditory abnormalities (Yehuda et al.,
2005). Omega-3 and -6 lipid supplementation by oral administra-
tion has proved beneﬁcial in several neurodegenerative patholo-
gies that involve oxidative stress (review in Kim et al., 2010). Since
myelin is a target for UCB, this therapeutic approach could be rel-
evant to the prevention of UCB-mediated toxicity in children. In
addition oral administration is possible, and side effects are not
expected. To the best of our knowledge, this approach has never
been tested.
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